Hims & Hers Health, Inc. (HIMS)
Hims & Hers Health, Inc. (HIMS) Suffers a Larger Drop Than the General Market: Key Insights
In the closing of the recent trading day, Hims & Hers Health, Inc. (HIMS) stood at $27.72, denoting a -6.7% move from the preceding trading day.
Hims & Hers Expands Australian Women's Health Platform With Hers
HIMS expands into Australia's women's healthcare market with the Hers launch, offering personalized treatments for weight, hormonal health and hair regrowth.
Why Hims & Hers Health, Inc. (HIMS) Dipped More Than Broader Market Today
Hims & Hers Health, Inc. (HIMS) closed the most recent trading day at $28.06, moving 5.01% from the previous trading session.
Reasons to Retain Hims & Hers Stock in Your Portfolio for Now
HIMS' top line is driven by demand for weight loss, international and AI momentum, but margin pressure and FDA uncertainty remain.
Tax Gain Harvesting: Tax Alpha With Raul Shah
Raul Shah emphasizes ultra-selective value investing, focusing on high-conviction positions like HIMS, NOW, UNH, and MSFT, prioritizing long-term cash flows over daily price moves. Tax gain harvesting is the 2nd most powerful tax strategy after Roth conversions, enabling investors to realize long-term capital gains at a 0% tax rate within specific income thresholds.
Hims & Hers Health, Inc. (HIMS) Is a Trending Stock: Facts to Know Before Betting on It
Hims & Hers Health (HIMS) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Hims & Hers Health, Inc. (HIMS) Stock Slides as Market Rises: Facts to Know Before You Trade
In the latest trading session, Hims & Hers Health, Inc. (HIMS) closed at $29.3, marking a -1.64% move from the previous day.
Hims & Hers: U.S. Revenue Reacceleration Is Reassuring, And Valuation Compression Is Compelling (Upgrade)
Hims & Hers is upgraded to a buy as revenue growth reaccelerates and valuation compresses, offering a compelling entry point. HIMS targets $6.5B+ revenue and $1.3B+ adjusted EBITDA by 2030, implying a >20% revenue and ~44% EBITDA CAGR from 2026-2030. Recent Q2 results showed 38% y/y revenue growth (31% organic), a strong U.S. rebound, and nearly 3M subscribers, despite margin pressure.
Hims & Hers Slides Nearly 7% as Legal Pressure Adds to Its Growing List of Risks
Shares of telehealth platform and direct-to-consumer (D2C) personal care products provider Hims & Hers Health NYSE: HIMS fell 6.7% on Wednesday, Sept. 23, as investors continue to weigh the fallout from August's disappointing earnings report and mounting legal pressure, including a securities class action filed earlier this month and an ongoing FTC lawsuit over alleged privacy and billing practices.
Hims & Hers Health, Inc. (HIMS) Falls More Steeply Than Broader Market: What Investors Need to Know
In the most recent trading session, Hims & Hers Health, Inc. (HIMS) closed at $27.93, indicating a -3.07% shift from the previous trading day.
HIMS Bulls Should Heed This Historic Chart Signal
Drugmaker Hims & Hers Health Inc (NYSE:HIMS) stock is moving 6.6% higher to trade at $29.34 this afternoon.
Why Is Hims & Hers Health (HIMS) Down 7.7% Since Last Earnings Report?
Hims & Hers Health (HIMS) reported earnings 30 days ago. What's next for the stock?
